<DOC>
	<DOCNO>NCT02216188</DOCNO>
	<brief_summary>This follow-up study ass safety clinical activity continue AFFITOPE速 PD01A vaccination patient Parkinson 's disease . Patients , already participate AFF008 involve receive one boost immunization AFFITOPE速 PD01A . One study site Vienna ( Austria ) involve . In addition , 8 patient offer participation within untreated control group .</brief_summary>
	<brief_title>Follow-up Study Assess One Boost Immunization With AFFITOPE速 PD01A With Regard Safety Clinical Activity</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Prior participation AFF008 AFF008E Written inform consent sign dated patient caregiver ( caregiver mandatory ) In investigator 's opinion , visual auditory impairment would reduce patient ' ability complete study questionnaire unable receive instruction Female patient childbearing potential eligible use medically accept contraceptive method Stable dos PD medication least 3 month prior Visit 0 entire trial period medication least 30 day prior Visit 1 consider relevant investigator Women childbearing potential without birth control pregnant woman Participation another clinical trial ( except AFF008E ) within 3 month Visit 0 History questionable compliance visit schedule ; patient expect complete clinical trial Autoimmune disease allergy component vaccine History cancer ( Exceptions : basal cell carcinoma , intraepithelial cervical neoplasia ) Active infectious disease Immunodeficiency Significant systemic illness psychiatric illness Alcoholism substance abuse Prior treatment experimental immunotherapeutics PD include IVIG ( exception AFFITOPE 速 PD01A ) , immunosuppressive drug treatment deep brain stimulation Venous status render impossible place i.v . access</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>